APA (7th ed.) Citation

C, J., C, E., A, J., J, M., C, B., R, D., . . . L, S. (2024). Case report: Sub-clinical extramedullary B-ALL in the setting of relapse following targeted therapy. Frontiers in immunology, 15, 1423487. https://doi.org/10.3389/fimmu.2024.1423487

Chicago Style (17th ed.) Citation

C, Johns, et al. "Case Report: Sub-clinical Extramedullary B-ALL in the Setting of Relapse Following Targeted Therapy." Frontiers in Immunology 15 (2024): 1423487. https://doi.org/10.3389/fimmu.2024.1423487.

MLA (9th ed.) Citation

C, Johns, et al. "Case Report: Sub-clinical Extramedullary B-ALL in the Setting of Relapse Following Targeted Therapy." Frontiers in Immunology, vol. 15, 2024, p. 1423487, https://doi.org/10.3389/fimmu.2024.1423487.